AI Article Synopsis
Article Abstract
Background: Twice-weekly tacrolimus ointment for mild to severe atopic dermatitis (AD) significantly reduced the number of flares and prolonged flare-free intervals compared with standard treatment in the CONTROL studies.
Methods: Post hoc analysis of data from the CONTROL studies was carried out on patients with moderate to severe disease. Patients applied tacrolimus 0.1% (adults; n = 183) or 0.03% (children; n = 166) ointment twice-daily for
Results: Twice-weekly treatment significantly reduced the number of flares and time to first flare (p < 0.001). Around three times as many patients in each study had no flares of any severity throughout the double-blind period in the twice-weekly treatment group compared with the standard treatment group (p < 0.001). Improvements in symptoms and quality of life with twice-weekly treatment were above those observed with standard treatment. Twice-weekly treatment was well tolerated.
Conclusions: A twice-weekly tacrolimus ointment regimen was effective in adults and children with moderate to severe AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/09546630903401488 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlocking the promise of mesenchymal stem cells and extracorporeal photopheresis to address rejection and graft failure in intestinal transplant recipients.
Hum Immunol
November 2024
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA. Electronic address:
Introduction: In patients with irreversible intestinal failure, intestinal transplant has become a standard treatment option. Graft failure secondary to acute or chronic cellular rejection continues to be a significant challenge following transplant. Even with optimal immune suppression, some patients continue to struggle with refractory rejection.
View Article and Find Full Text PDFSkin and systemic inflammation in adults with atopic dermatitis before and after whole-body topical betamethasone 17-valerate 0.1% or tacrolimus 0.1% treatment: A randomized controlled study.
J Eur Acad Dermatol Venereol
July 2024
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Atopic dermatitis (AD) is mainly driven by type 2 inflammation and often treated with topical agents. Studies comparing differences in biomarkers between these treatments are lacking.
Objectives: The aim of this study was to evaluate the effects of topical betamethasone 17-valerate 0.
Rapid resolution of non-segmental vitiligo in a patient treated with abrocitinib: A case report.
SAGE Open Med Case Rep
February 2024
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Article Synopsis
- - Vitiligo is an autoimmune skin disorder that causes loss of pigment, and new treatments like Janus Kinase inhibitors are showing promise for managing it.
- - A case study involving a 61-year-old man with resistant vitiligo showed significant improvement after using oral Abrocitinib, a JAK inhibitor, for 2 months after prior treatments plateaued.
- - More research, including ongoing clinical trials, is essential to evaluate the long-term effectiveness and safety of these oral Janus Kinase inhibitors for treating vitiligo.
Efficacy and safety of 308-nm Excimer lamp combined with Tacrolimus 0.1% ointment vs Tacrolimus 0.1% ointment as monotherapy in treating children with limited vitiligo: a randomized controlled trial.
J Dermatolog Treat
December 2024
Sheffield Dermatology Research, IICD, University of Sheffield, UK.
Objective: This study aims to assess the efficacy and safety of combining the 308-nm Excimer lamp with Tacrolimus 0.1% ointment, compared to Tacrolimus 0.1% ointment monotherapy, for treating pediatric vitiligo involving less than 10% of the body surface area.
View Article and Find Full Text PDFCase report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.
Front Pediatr
February 2023
Division of Pediatric Rheumatology, Johns Hopkins All Children's Hospital, St Petersburg, FL, United States.
Introduction: Macrophage activation syndrome (MAS), a secondary form of hemophagocytic lymphohistiocytosis, is a serious life-threatening complication associated with systemic juvenile idiopathic arthritis (sJIA). MAS is characterized by fever, hepatosplenomegaly, liver dysfunction, cytopenias, coagulation abnormalities, and hyperferritinemia and may progress to multiple organ failure and death. Overproduction of interferon-gamma is a major driver of hyperinflammation in murine models of MAS and primary hemophagocytic lymphohistiocytosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!